UBS AM
APGE

UBS AM’s Apogee Therapeutics APGE Stock Holding History

UBS AM’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.82M Buy
66,433
+10,081
+18% +$908K ﹤0.01% 1314
2026
Q1 		$4.74M Buy
56,352
+6,547
+13% +$475K ﹤0.01% 1577
2025
Q4 		$3.76M Buy
49,805
+18,642
+60% +$1.17M ﹤0.01% 1600
2025
Q3 		$1.24M Sell
31,163
-23,899
-43% -$913K ﹤0.01% 1938
2025
Q2 		$2.39M Buy
55,062
+19,336
+54% +$736K ﹤0.01% 2070
2025
Q1 		$1.33M Buy
35,726
+3,465
+11% +$134K ﹤0.01% 2185
2024
Q4 		$1.46M Buy
32,261
+20
+0.1% +$1.02K ﹤0.01% 2190
2024
Q3 		$1.89M Sell
32,241
-2,162
-6% -$104K ﹤0.01% 2063
2024
Q2 		$1.35M Buy
+34,403
New +$1.67M ﹤0.01% 2209

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

UBS AM's APGE Position: Q2 2026 in Review

UBS AM increased its Apogee Therapeutics (APGE) stake by 18% in Q2 2026, buying an estimated $908K and bringing the position to 66,433 shares worth $8.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

UBS AM first reported a position in APGE in Q2 2024 and has held it in 9 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • UBS AM held 66,433 shares of Apogee Therapeutics worth $8.82M as of Q2 2026.
  • UBS AM bought 10,081 Apogee Therapeutics shares in Q2 2026, an estimated $908K.
  • Apogee Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1314 holding.
  • UBS AM first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.